

CURRICULUM VITAE

Jeromie M. Ballreich, Ph.D., M.H.S

PERSONAL DATA

Home Address

[REDACTED]

Tel: [REDACTED]

Work Address

Johns Hopkins Bloomberg School of Public Health
624 North Broadway, Room 303
Baltimore, MD 21205
Tel: (814) 599-6001
E-mail: jballre2@jhu.edu
Twitter: @jeromie_b
Pronouns: He/him/his

EDUCATION AND TRAINING

PhD 2017 *Johns Hopkins Bloomberg School of Public Health, Health Economics*

MHS 2012 *Johns Hopkins Bloomberg School of Public Health, Health Economics*

BA 2010 *Lafayette College, Mathematics and Economics*

PROFESSIONAL EXPERIENCE

Johns Hopkins University

Associate Research Professor, Health Policy Management, Johns Hopkins Bloomberg School of Public Health, October 2023 - present

Associate Scientist, Health Policy Management, Johns Hopkins Bloomberg School of Public Health, October 2022 – October 2023

Assistant Scientist, Health Policy Management, Johns Hopkins Bloomberg School of Public Health, May 2017 – October 2022

Director of Health Economics and Outcomes Research Program, Health Policy Management, Johns Hopkins Bloomberg School of Public Health, June 2017 – present

Investigator, Center of Excellence in Regulatory Science and Innovation, Johns Hopkins Bloomberg School of Public Health, July 2021 – present

Core Faculty, Hopkins Business of Health Initiative, Johns Hopkins Bloomberg School of Public Health, June 2022 – present

Core Faculty, Roger C. Lipitz Center for Integrated Health Care, Johns Hopkins Bloomberg School of Public Health, June 2018 – present

Core Faculty, Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, June 2017 – present

Other Non-JHU Professional Experience

Scientific Advisor, Monument Analytics LLC, July 2017-present

PROFESSIONAL ACTIVITIES

Advisory Board Member, Rancho Los Amigos National Rehabilitation Center

Member, American Society of Health Economists

Member, International Society of Pharmacoeconomics and Outcomes Research

Member, ISPOR Oncology Modeling Special Interest Group, 2016-2017

Member, Society of Medical Decision Making

Member and Regional Chairperson, Pennsylvania Governor's Advisory Committee for People with Disabilities, 2007-2011

EDITORIAL ACTIVITIES

Peer Reviewer

BMJ

Health Economics

International Journal of Technology Assessment of Health Care

JAMA

JAMA Internal Medicine

JAMA Network Open

Journal of General Internal Medicine

Journal of Health Care for the Poor and Underserved

Journal of Managed Care & Specialty Pharmacy

Journal of Pharmaceutical Policy

Medical Care

Pediatrics

Pharmaceutical Sciences

Pharmacoeconomics

PLOS One

Value in Health

HONORS AND AWARDS

Bloomberg School of Public Health Excellence in Teaching for Economic Evaluation I, 2023

Bloomberg School of Public Health Excellence in Teaching for Economic Evaluation I, 2022

Bloomberg School of Public Health Excellence in Teaching for Economic Evaluation I, 2021

Bloomberg School of Public Health Excellence in Teaching for Economic Evaluation III, 2020

Best Student Podium Research Presentation Award, International Society of Pharmacoeconomics and Outcomes Research, Washington DC 2016

The June Culley Scholarship in Health Policy and Management Doctoral Award, 2016

The Jayne Koskinas Ted Giovanis Foundation for Health and Policy Dissertation Support Grant, 2015

NRSA-HSR&P Training Grant in the Department of Health Policy and Management at the Johns Hopkins Bloomberg School of Public Health, 2012-2015

Excel Scholar, Lafayette College, 2010

Trustee Scholar, Lafayette College, 2002-2004

PUBLICATIONS

** indicates a mentored student or post-doctoral fellow*

Journal Articles

1. Mudumba, R.*, Chan, H. H.*, Cheng, Y. Y.*, Wang, C. C.*, Correia, L., **Ballreich, J.**, & Levy, J. (2024). Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States. *Value in Health*, 27(2), 153-163.
2. **Ballreich, J.**, Kim, H. S.*, & Socal, M. (2024). Pediatric Drugs, Accelerated Approval, and Prospects for Reform. *Pediatric Drugs*, 26(1), 5-8.
3. Odouard, I. C., Anderson, G. F., Alexander, G. C., & **Ballreich, J.** (2023). Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations. *Journal of Managed Care & Specialty Pharmacy*, 1-10.

4. Fabius, C.D., Okoye, S.M., Wu, M.M., Jopson, A.D., Chyr, L.C., Burgdorf, J.G., **Ballreich, J.**, Scerpella, D. and Wolff, J.L., 2023. The Role of Place in Person-and Family-Oriented Long-Term Services and Supports. *The Milbank Quarterly*. 2023;101(4):0728.
5. Park, S. *, Ward, T. *, Sudimack, A., Cox, S., & Ballreich, J. (2023). Cost-effectiveness analysis of a digital Diabetes Prevention Program (dDPP) in prediabetic patients. *Journal of Telemedicine and Telecare*, 2023;0(0). doi:10.1177/1357633X231174262
6. Reitsma, M. B., Dusetzina, S. B., **Ballreich, J. M.**, Trujillo, A. J., & Mello, M. M. (2023). Examining Opportunities to Increase Savings From Medicare Price Negotiations. *JAMA internal medicine*, 183(6), 581-588.
7. **Ballreich, J.**, Socal, M., Bennett, C. L., Xuan, A., Trujillo, A., & Anderson, G. (2023). Accelerated approval drug labels often lack information for clinical decision-making. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 43(4), 300-304.'
8. Socal, M. P., Crane, M. A., **Ballreich, J.**, & Anderson, G. F. (2022). The New Medicare Part D Out-Of-Pocket Cap Will Have Unintended Consequences. Here's How To Address Them. *Health Affairs Forefront*. DOI: 10.1377/forefront.20221005.69841
9. Patenaude, B., & **Ballreich, J.** (2022). Modeling the potential economic benefits of an oral SARS-CoV-2 vaccine during an outbreak of COVID-19. *BMC public health*, 22(1), 1792.
10. **Ballreich, J.**, Socal, M., & Anderson, G. F. (2022). Anticipating Reforms to the Prescription Drug User Fees Act. *JAMA Network Open*, 5(11), e2239341-e2239341.
11. Trujillo, A. J., Gutierrez, J. C., Garcia Morales, E. E., Socal, M., **Ballreich, J.**, & Anderson, G. (2022). Trajectories of prices in generic drug markets: what can we infer from looking at trajectories rather than average prices?. *Health Economics Review*, 12(1), 37.
12. **Ballreich, J.**, Levensgood, T., & Conti, R. M. (2022). Opportunities and Challenges of Generic Pre-Exposure Prophylaxis Drugs for HIV. *Journal of Law, Medicine & Ethics*, 50(S1), 32-39.
13. Killelea A, Johnson J, Dangerfield DT, Beyrer C, McGough M, McIntyre J, Gee RE, **Ballreich J**, Conti R, Horn T, Pickett J. Financing and Delivering Pre-Exposure Prophylaxis (PrEP) to End the HIV Epidemic. *Journal of Law, Medicine & Ethics*. 2022;50(S1):8-23.
14. Emmett, S. D., Platt, A., Turner, E. L., Gallo, J. J., Labrique, A. B., Inglis, S. M., ...**Ballreich, J.M.**, & Robler, S. K. (2022). Mobile health school screening and

telemedicine referral to improve access to specialty care in rural Alaska: a cluster-randomised controlled trial. *The Lancet Global Health*, 10(7), e1023-e1033.

15. **Ballreich, J.**, Socal, M., Bennett, C. L., Schoen, M. W., Trujillo, A., Xuan, A., & Anderson, G. (2022). Medicare Spending on Drugs With Accelerated Approval. *Annals of Internal Medicine*.
16. Alexander, G. C., **Ballreich, J.**, Mansour, O., & Dowdy, D. W. (2022). Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model. *Addiction*, 117(4), 969-976.
17. Hussaini, S. Q., Gupta, A., Anderson, K. E., **Ballreich, J. M.**, Nicholas, L. H., & Alexander, G. C. (2022). Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019. *JAMA Network Open*, 5(3), e221117-e221117.
18. Plummer, E., Socal, M. P., **Ballreich, J. M.**, Anderson, G. F., & Bai, G. (2022, May). Trends of Prescription Drug Manufacturer Rebates in Commercial Health Insurance Plans, 2015-2019. In *JAMA Health Forum* (Vol. 3, No. 5, pp. e220888-e220888). American Medical Association.
19. Patenaude, B., & **Ballreich, J.** (2022). Estimating & Comparing Greenhouse Gas Emissions for Existing Intramuscular COVID-19 Vaccines and a Novel Thermostable Oral Vaccine. *The Journal of Climate Change and Health*, 100127.
20. **Ballreich, J.**, Ezebilo, I. *, Khalifa, B. A. *, Choe, J., & Anderson, G. (2022). Coverage of genetic therapies for spinal muscular atrophy across fee-for-service Medicaid programs. *Journal of managed care & specialty pharmacy*, 28(1), 39-47.
21. Wang, L.* , Hong, H., Alexander, G. C., Brawley, O. W., Paller, C. J., & **Ballreich, J.** (2021). Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis. *Value in Health*.
22. Yong, M.* , Wu, Y. Q., Howlett, J., **Ballreich, J.**, Walgama, E., & Thamboo, A. (2021, December). Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease. In *International Forum of Allergy & Rhinology* (Vol. 11, No. 12, pp. 1626-1636).
23. **Ballreich, J.**, Bennet, C., Moore, T. J., & Alexander, G. C. (2021). Medicare Expenditures of Atezolizumab for a Withdrawn Accelerated Approved Indication. *JAMA Oncology*, 7(11), 1720-1721.
24. George, T.* , **Ballreich, J.**, Trujillo, A., & Anderson, G. (2021). The Association Between Drug Approvals and Burden of Disease From 1990 to 2017. *Journal of General Internal Medicine*, 36(11), 3615-3617.

25. Alexander, G. C., **Ballreich, J.**, Mansour, O., & Dowdy, D. W. (2021). Effect of reductions in opioid prescribing on opioid use disorder and fatal overdose in the United States: a dynamic Markov model. *Addiction*.
26. **Ballreich, J.**, Jin, J., Kundu, P., & Chatterjee, N. (2021). Provider and Patient Characteristics of Medicare Beneficiaries Who Are High-Risk for COVID-19 Mortality. *Journal of General Internal Medicine*, 36(7), 2189-2190.
27. Frick, K. D., Kacker, S., & **Ballreich, J.** (2021). Consider expenditure controls' impacts on equity. *EClinicalMedicine*, 36.
28. Padula, W. V., Malaviya, S., Reid, N. M., Cohen, B. G., Chinguanco, F., **Ballreich, J.**, ... & Alexander, G. C. (2021). Economic value of vaccines to address the COVID-19 pandemic: a US cost-effectiveness and budget impact analysis. *Journal of Medical Economics*, 24(1), 1060-1069.
29. **Ballreich, J. M.**, Gross, C. P., Powe, N. R., & Anderson, G. F. (2021). Allocation of National Institutes of Health Funding by Disease Category in 2008 and 2019. *JAMA Network Open*, 4(1), e2034890-e2034890.
30. **Ballreich, J.**, Mansour, O., Hu, E., Chinguanco, F., Pollack, H. A., Dowdy, D. W., & Alexander, G. C. (2020). Modeling mitigation strategies to reduce opioid-related morbidity and mortality in the US. *JAMA Network Open*, 3(11), e2023677-e2023677.
31. **Ballreich, J.**, Ezebilo, I., & Sharfstein, J. (2020). Affording genetic therapies in the Medicaid program. *JAMA Pediatrics*, 174(6), 523-524.
32. Yong, M.*, Liang, J., **Ballreich, J.**, Lea, J., Westerberg, B. D., & Emmett, S. D. (2020). Cost-effectiveness of school hearing screening programs: A scoping review. *Otolaryngology–Head and Neck Surgery*, 162(6), 826-838.
33. Murimi-Worstell, I. B., **Ballreich, J. M.**, Seamans, M. J., & Alexander, G. C. (2019). Association between US Pharmacopeia (USP) monograph standards, generic entry and prescription drug costs. *PloS one*, 14(11).
34. Levin, J., **Ballreich, J.**, Socal, M., Bai, G., & Anderson, G. (2019). Consolidated Drug Purchasing Across Federal Agencies: A Policy to Decrease Cost Sharing for Medicare Beneficiaries. *Journal of Health Care Finance*.
35. Heyward, J., Jones, C.M., Compton, W.M., Lin, D.H., Losby, J.L., Murimi, I.B., Baldwin, G.T., **Ballreich, J.M.**, Thomas, D.A., Bicket, M.C. and Porter, L., 2018. Coverage of nonpharmacologic treatments for low back pain among US public and private insurers. *JAMA Network Open*, 1(6), pp.e183044-e183044.

36. Lin, D.H., Jones, C.M., Compton, W.M., Heyward, J., Losby, J.L., Murimi, I.B., Baldwin, G.T., **Ballreich, J.M.**, Thomas, D.A., Bicket, M. and Porter, L., 2018. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers. *JAMA Network Open*, 1(2), pp.e180235-e180235.
37. Padula, W. V., **Ballreich, J.**, & Anderson, G. F. (2018). Paying for Drugs After the Medicare Part D Beneficiary Reaches the Catastrophic Limit: Lessons on Cost Sharing from Other US Policy Partnerships Between Government and Commercial Industry. *Applied health economics and health policy*, 16(6), 753-763.
38. Alexander, G. C., **Ballreich, J.**, Socal, M. P., Karmarkar, T., Trujillo, A., Greene, J., ... & Anderson, G. (2017). Reducing Branded Prescription Drug Prices: A Review of Policy Options. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy*, 37(11), 1469-1478.
39. **Ballreich, J.**, Alexander, G. C., Socal, M., Karmarkar, T., & Anderson, G. (2017). Branded prescription drug spending: a framework to evaluate policy options. *Journal of pharmaceutical policy and practice*, 10(1), 31.
40. Anderson, G. F., **Ballreich, J.**, Bleich, S., Boyd, C., DuGoff, E., Leff, B., ... & Wolff, J. (2015). Attributes common to programs that successfully treat high-need, high-cost individuals. *The American Journal of Managed care*, 21(11), e597-e600.
41. Sherry, M., Wolff, J., **Ballreich, J.**, DuGoff, E., Davis, K., & Anderson, G.F. (2016). Bridging the Silos of Service Delivery for High-Need, High-Cost Individuals. *Population Health Management*, 19(6), 421-428.
42. Kleweno, C. P., O'Toole, R. V., **Ballreich, J.**, & Pollak, A. N. (2015). Does Fracture Care Make Money for the Hospital? An Analysis of Hospital Revenues and Costs for Treatment of Common Fractures. *Journal of Orthopaedic Trauma*, 29(7), e219-e224.
43. Butz, A. M., Ogborn, J., Mudd, S., **Ballreich, J.**, Tsoukleris, M., Kub, J., ... & Bollinger, M. E. (2015). Factors associated with high short-acting β 2-agonist use in urban children with asthma. *Annals of Allergy, Asthma & Immunology*, 114(5), 385-392.
44. Davis, K., & **Ballreich, J.** (2014). Equitable access to care—how the United States ranks internationally. *New England Journal of Medicine*, 371(17), 1567-1570.

Book Chapter

1. Anderson, G.F., **Ballreich, J.**, & Bhadelia, A. Ethics of Policy Change And Health Reform. Oxford Handbook of Public Health Ethics. (March 2019).

White Papers

1. Social, M., **Ballreich, J.**, Chyr, L., & Anderson, G. (2020) *Biosimilar Medications – Savings Opportunities for Large Employers Based on Analysis of Actual Employer Spending, With Suggestions for Plan Design Strategies and Public Policy Options to Accelerate Uptake.*
2. **Ballreich, J.**, Anderson, G., et al. (2019) *Pharmaceuticals: Innovation, Access, And Affordability Chartbook.* Access: https://www.jhsph.edu/research/affiliated-programs/johns-hopkins-drug-access-and-affordability-initiative/_includes/jhdaai_chartbook_2019.pdf
3. Dickson, S. & **Ballreich, J.** (2019) *How much can Pharma Lose? A Comparison of Returns Between Pharmaceutical and Other Industries.* Access: <https://www.westhealth.org/resource/how-much-can-pharma-lose/>
4. Social M., Patel P., **Ballreich J.**, & Anderson G. (2017) Monitoring price hikes and utilization of off-patent drugs. Memo to Joshua Auerbach, Assistant MD Attorney General.

PRACTICE ACTIVITIES

Presentation on mail order pharmacy use for the Johns Hopkins' Clinical, Social, and Scientific Foundations of Geriatric Medicine Grand Rounds. February 2024

Testimony to the US House Ways and Means Committee on “Chronic drug shortages.” February 2024

“Medicare’s New Drug Price Negotiation Program” George Mason Health Policy Speaker Series. Panelist, June 2023.

Consultation to Centers for Medicare and Medicaid Services on Pharmaceutical Policies. 2017-present

Consultation to U.S. Senate Finance Committee on Pharmaceutical Policies. 2017-present

Consultation to U.S. Senate Energy and Commerce Committee on Pharmaceutical Policies. 2021-present

Consultation to U.S. Congressional Health, Education, Labor Committee on Pharmaceutical Policies. 2017-present

Johns Hopkins Bloomberg School of Public Health Diversity Equity, and Inclusion strategic plan committee. 2020.

Testimony to the State of Maine on the impact of a proposed opioid fee. August 2019

Testimony to the State of Delaware on the impact of a proposed opioid fee. July 2019

“What does it mean to be high-needs: a Patient’s Perspective” Presentation at National Academy of Medicines Workshop on Models of Care for High-need Patients Workshop. July 2015.

“Needs, Barriers, and Opportunities Associated with Using Health IT: a personal Perspective” Presentation at Accessibility and Usability in Health Information Technology (HIT): A Research and Action Conference to Empower People with Disabilities, Older Adults, and Caregivers. September 2015.

“Community Services from a Patient’s Perspective” Presentation at Patient-Centered Primary Care Collaborative Annual Meeting. November 2015.

RESEARCH FINDING DISSEMINATION THROUGH MEDIA APPEARANCES

Selected Media Coverage

1. Healio. *Allocation of NIH funding demonstrates ‘great stability’ over time.* (2021, January 27). <https://www.healio.com/news/neurology/20210127/allocation-of-nih-funding-demonstrates-great-stability-over-time>
2. Healio. *‘Substantial’ price increases continue for most popular brand-name drugs.* (2019, May 31). <https://www.healio.com/news/endocrinology/20190531/substantial-price-increases-continue-for-most-popular-brandname-drugs>
3. Consumer Health News. *U.S. Ranks Last Among Wealthy Nations in Access to Health Care.* (2014, October 22). Consumer Health News | HealthDay. <https://consumer.healthday.com/general-health-information-16/emergencies-and-first-aid-news-227/u-s-ranks-last-among-wealthy-nations-in-access-to-health-care-692991.html>

PART II

TEACHING

Doctoral Students Advised

Ping-Ying Chiang, DrPH, expected 2023
Men Shuai, DrPH, expected 2025

Masters Students Advised

Vanessa Hendrickson, expected 2024
Michael Forbes, expected 2024
Lyssa Darra, expected 2024
Neenah Young, MHS, 2023
Riley Strayer, MHS, 2023
Su Yi Cheng, MHS, 2023
Chan Sohn, MHS, 2023
Anisha Paul, MHS, 2023
Hyung-Seok Kim, MHS, 2023
Daniel Stellato, MHS, 2023
Hui-Hsuan Chan, MHS, 2022
Yuan-Yuan Cheng, MHS, 2022
Caroline Doherty, MHS, 2022
Yosef Laudencia, MHS, 2022
Yu-Shan Lee, MHS, 2022
Aurelia Little, MHS, 2022
Hanxiao Ma, MHS, 2022
Rahul Mudumba, MHS, 2022
Zeyu Pan, MHS, 2022
Sooyeol Park, MHS, 2022
Andrew Sudimack, MHS, 2022
Chien-Chen Wang, MHS, 2022
Wanli Wang, MHS, expected 2022
Trevor Ward, MHS, expected 2022
Ziyi Xia, MHS, expected 2022
Ning Zhou, MHS, expected 2022
Mina Dang, MHS, 2021
Tharani Murali, MHS, 2021
Salma Kahn, MHS, 2021
Sunyue Zhou, MHS, 2021
Daniel Boada, MHS, 2020
Yijao Chen, MHS, 2020
Pei-Lin Huang, MHS, 2020

Zongzong Li, MHS, 2020
Kuan Peng, MHS, 2020
Nada Boulam, MHS, 2019
Justin Chen, MHS, 2019
Vincent DeMario, MHS, 2019
Sasmira Matta, MHS, 2019
Danyang Wang, MHS, 2019
Elise McNulty, MHS, 2019
Akihito Yoshida, MHS, 2019
Chu Zhuang, MHS, 2019
Marcella Kelley, MHS, 2018
Jeffrey Yu, MHS, 2018
Rahul Chandler, MHS, 2018
Yutong Chen, MHS, 2018
Danyue Hu, MHS, 2018
Yiqun Luan, MHS, 2018
Sreelekshmi Rajeswari, MHS, 2018

Capstone Advisees

Neenah Young, 2023
Riley Strayer, 2023
Su Yi Cheng, 2023
Chan Sohn, 2023
Anisha Paul, 2023
Hyung-Seok Kim, 2023
Daniel Stellato, MHS, 2023
Hui-Hsuan Chan, MHS, 2022
Yuan-Yuan Cheng, MHS, 2022
Caroline Doherty, MHS, 2022
Yosef Laudencia, MHS, 2022
Yu-Shan Lee, MHS, 2022
Aurelia Little, MHS, 2022
Hanxiao Ma, MHS, 2022
Rahul Mudumba, MHS, 2022
Zeyu Pan, MHS, 2022
Sooyeol Park, MHS, 2022
Daniel Stellato, MHS, 2023
Andrew Sudimack, MHS, 2022
Chien-Chen Wang, MHS, 2022
Wanli Wang, MHS, 2022
Trevor Ward, MHS, 2022
Ziyi Xia, MHS, 2022
Ning Zhou, MHS, 2022
Benjamin Wormser, MPH, 2021

Tharani Murali, MHS, 2021
Salma Kahn, MHS, 2021
Sunyue Zhou, MHS, 2021
Daniel Boada, MHS, 2020
Michael Yong, MPH, 2020
Nada Boulam, MHS, 2019
Danyang Wang, MHS, 2019
Akihito Yoshida, MHS, 2019
Chu Zhuang, MHS, 2019
Audrey Zhang, MPH, 2019

Department Oral Exam Participation

Men Shuai (2024)
Katelyn Yoo (2023)
Luke Aldridge (2020) Alternate

Final Oral Exam Participation

Lin Wang (2021)

Instructor

Instructor, HPM #PH.313.601 Economic Evaluation I (1st term). 2020-current

Instructor, HPM #PH.313.790 Introduction to Economic Evaluation (4th term). 2020-current.

Instructor, HPM #PH.313.603 Economic Evaluation III (3rd term). 2019.

Instructor, HPM #PH.313.861 Public Health Economics Seminar (3rd and 4th term). 2018-2021.

Instructor, HPM #PH.313.865 MHS Capstone in Health Economics (3rd term and 4th term). 2018-current.

Guest Lecturer

HPM #PH.550.608.91 Problem Solving in Public Health 2019-current

HPM #PH.308.630.01 US Pharmaceutical Policy 2019-current

RESEARCH GRANT PARTICIPATION

Active Grants

Title: How might Part D Plans respond to the Inflation Reduction Act?

Sponsor: Commonwealth Fund

Role: Principal Investigator

Effort: 1.2 calendar months

Amount: \$50,000

Period of Performance: 5/1/23-4/31/24

Brief description: The purpose of this project is to assess potential party plan responses to changes in the benefit design prescribed in the Inflation Reduction Act of 2022.

Principal PI: Dr. Jeromie Ballreich

Title: Comparing adherence and spending on pharmacologic treatments among Medicare Part D beneficiaries with Alzheimer's disease and related dementias who use mail order versus retail pharmacies

Sponsor: Hopkins' Economics of Alzheimer's Disease and Services Center

Role: Investigator

Effort: 1.2 calendar months

Amount: \$50,000

Period of Performance: 7/1/23-12/31/23

Brief description: The purpose of this project is to evaluate differences in pharmacological treatment adherence and spending between Mail order versus retail pharmacies in the Medicare Part D population

Principal PI: Dr. Mariana Socal

Title: Effectiveness of Digital versus In-person Diabetes Prevention Programs

Sponsor: NIDDK

Role: Investigator

Effort: .6 calendar months

Amount: \$2,862,148

Period of Performance: 1/1/2022-9/30/2024

Brief Description: The major goals are to evaluate the real-world effectiveness of a fully-automated digital diabetes prevention program for weight reduction, promotion of physical activity, and lowering of hemoglobin A1C (a measure of average blood glucose control) compared to standard of care in-person diabetes prevention programs.

PI: Dr. Nestor Mathioudakis

Title: Johns Hopkins Drug Access and Affordability Initiative

Sponsor: Laura and John Arnold Foundation

Role: Investigator

Effort: 9.6 calendar months

Amount: \$4,000,000

Period of Performance: 11/1/21-12/31/23

Brief description: The purpose of this project is to continue work done in a previous grant that examines the impact of drug prices on access and affordability; and develop policy options within the United States.

Principal PI: Dr. Gerard Anderson

Title: Community Level Emerging Substance Misuse Simulation

Sponsor: US Food and Drug Administration

Role: Principal Investigator

Effort: 2.4 calendar months

Amount: \$61,318

Period of Performance: 9/1/21-12/31/23

Brief description: The purpose of this project is to advise the US Food and Drug Administration on the validation and development of an agent-based model for localized opioid epidemics

Principal PI: Dr. Jeromie Ballreich

Completed Grants

Title: Johns Hopkins Drug Access and Affordability Initiative

Sponsor: Laura and John Arnold Foundation

Role: Investigator

Effort: 9.6 calendar months

Amount: \$4,251,144

Period of Performance: 5/1/19-10/31/21

Brief description: The purpose of this project is to continue work done in a previous grant that examines the impact of drug prices on access and affordability; and develop policy options within the United States.

Principle PI: Dr. Gerard Anderson

Title: Drug pricing

Sponsor: Laura and John Arnold Foundation

Role: Investigator

Effort: 6 calendar months

Amount: \$3,589,000

Period of Performance: 11/1/16-5/31/19

Brief description: The purpose of this project is to examine the impact of drug prices on access and affordability; and develop policy options within the United States.

Principle PI: Dr. Gerard Anderson

Title: Major Extremity Trauma Research Consortium (METRC II)

Funded by: Department of Defense

Role: Analyst

Effort: 3.6 calendar months

Amount: \$34,607,859

Period of Performance: 09/29/2010-09/28/2018

Brief Description: The purpose of this multi-center consortium is to conduct studies that address the critical research and treatment issues challenging recovery from severe extremity trauma.
Principle PI: Dr. Ellen Mackenzie

PRESENTATIONS

“Cost-Effectiveness of the Technology-Enhanced Community Health Nursing Intervention for Adolescents and Young Adults with Pelvic Inflammatory Disease” Society of Adolescent Health Annual Meeting March 2022.

“Patient Affordability in Oncology” invited presentation at Janssen Pharmaceuticals April 2019.

“Economic Costs of Pediatric Asthma among Urban Youth” *Top 10% Poster*, 2019 ISPOR Annual Meeting.

“Prevalence of Medicare Beneficiaries with a Recent Diagnosis of Chronic Hepatitis C In 2016” 2019 ISPOR Annual Meeting.

“Variation of Pharmacotherapies for Opioid Use Disorder across State Medicaid Programs” 2019 ISPOR Annual Meeting.

“An Empirical Evaluation of Pharmacy “Gag” Rules in the US” 2018 ISPOR Annual Meeting.

“Variation in Hepatitis C Drug Utilization across State Medicaid Programs” 2018 ISPOR Annual Meeting.

“Coverage of Non-Pharmacologic Treatments for Lower Back Pain Among Public And Private Insurers In The United States” 2018 ISPOR Annual Meeting.

“Dual Approaches for Estimating Drug Development Costs.” *Top 10% Poster*, 2017 ISPOR Annual Meeting.

“Reducing Prescription Drug Spending Costs: A Review Of Policy Options.” 2017 ISPOR Annual Meeting.

“Economic evaluation of an Automated Retinal Image Analysis in Australian Aboriginal and Torres Strait Islander populations for detection of Diabetic Retinopathy.” *Best Student Research Podium* at 2016 ISPOR Annual Meeting.

“Does Fracture Care Make Money for the Hospital? An Analysis of Revenue and Cost for Treatment of Common Fractures”, *Best Poster* in the Trauma classification at the 2014 AAOS Annual Meeting.

“Factors Associated with Recurrent ED Visits In Minority Children With Persistent Asthma”, Poster at American Thoracic Society Annual Meeting. May 2015.

“Projecting Enrollment Across Multiple Studies in a Clinical Trials Consortium: a Forecasting Tool” Professional poster presentation at the DIA 2015 51st Annual Meeting. June 2015.

ADDITIONAL INFORMATION

Dr. Ballreich is a health economist specializing in three main areas: pharmaceutical economics and policy; economic evaluations; and high-cost/high-needs patient populations. Dr. Ballreich has gained expertise in these areas by working alongside eminent faculty at Johns Hopkins Bloomberg School of Public Health during his education and as a faculty. His peer-reviewed work has been published in *New England Journal of Medicine*, *American Journal of Managed Care*, and other academic journals. He has been an invited workshop participant and presenter at the National Academy of Medicine, International Society of Pharmacoeconomics and Outcomes Research annual meeting, and other professional societies.

His primary work currently focuses on pharmaceutical pricing policy with the Johns Hopkins Drug Access and Affordability Initiative (JHDAAI). Dr. Ballreich directs the Master in Health Economics and Outcomes Research program at the Johns Hopkins Bloomberg School of Public Health.